Current Oncology | Top Cited Papers in 2022 in the Section “Thoracic Oncology”

As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers in the Section “Thoracic Oncology” shown below:

1. “ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date”
by Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier
Curr. Oncol. 2022, 29(2), 641–658; https://doi.org/10.3390/curroncol29020057
Available online: https://www.mdpi.com/1718-7729/29/2/57

2. “Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150

3. “Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24

4. “Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer”
by Diana N. Ionescu, Tracy L. Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather, Zhaolin Xu, Normand Blais, Parneet K. Cheema, Quincy S.-C. Chu, Barbara Melosky et al.
Curr. Oncol. 2022, 29(7), 4981–4997; https://doi.org/10.3390/curroncol29070396
Available online: https://www.mdpi.com/1718-7729/29/7/396

5. “Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review”
by Anna Rekowska, Piotr Rola, Magdalena Wójcik-Superczyńska, Izabela Chmielewska, Paweł Krawczyk and Janusz Milanowski
Curr. Oncol. 2022, 29(5), 3531–3539; https://doi.org/10.3390/curroncol29050285
Available online: https://www.mdpi.com/1718-7729/29/5/285

6. “Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer”
by Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein et al.
Curr. Oncol. 2022, 29(7), 4428–4437; https://doi.org/10.3390/curroncol29070352
Available online: https://www.mdpi.com/1718-7729/29/7/352

7. “Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy”
by Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp and Frank Griesinger
Curr. Oncol. 2022, 29(9), 6628–6634; https://doi.org/10.3390/curroncol29090520
Available online: https://www.mdpi.com/1718-7729/29/9/520

8. “HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature”
by Laurent Mathiot, Guillaume Herbreteau, Siméon Robin, Charlotte Fenat, Jaafar Bennouna, Christophe Blanquart, Marc Denis and Elvire Pons-Tostivint
Curr. Oncol. 2022, 29(5), 3748–3758; https://doi.org/10.3390/curroncol29050300
Available online: https://www.mdpi.com/1718-7729/29/5/300